JOHNSON & JOHNSON

How Johnson & Johnson Is Doing Its Part to Tackle the Worldwide Mental Health Epidemic

Johnson & Johnson is No. 5 on the DiversityInc Top 50 Companies list


(Originally published on JNJ.com)

Facing Down a Mental Health Epidemic

Worldwide, an estimated 1 billion people suffer from anxiety, 300 million people are touched by depression, 60 million suffer from bipolar affective disorder, about 21 million are affected by schizophrenia or other severe psychoses and nearly 50 million people have dementia. By 2050, the dementia figure alone is expected to grow to 152 million, representing a 204% increase.

Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson

Meanwhile, such challenges as lack of resources and trained healthcare providers, inaccurate assessment and social stigma compound the inability to address the mental health epidemic effectively.

While this urgent need is escalating, the science around mental health and brain diseases remains complex, and public and private funding for this research does not match the need nor the investment in other disease areas.

Despite advances in neuroscience and increased understanding of the brain and brain disorders, the current growing prevalence of mental illness—particularly in young people—and Alzheimer’s, as well as gaps in research and care, have the potential to create a global crisis.

But there is a solution: disruptive innovation and international, open collaboration.

Science and technology offer us unprecedented opportunities in these areas. To take advantage of them, we in academia, biotech, government, regulatory, patient groups and civic society must all work together to solve some key challenges.

First is the need for an integrated research approach combining disease risk assessment, early diagnosis and disease interception with supportive treatment interventions.

Second, we need strong public-private partnerships to spur progress in such areas as better detecting at-risk individuals, and harnessing “big data” and real-world evidence to develop more innovative approaches to clinical trial design, drug development and novel regulatory pathways in the brain.

Finally, we must continue exploring innovative financing mechanisms to trigger investment. With a global funding mechanism, we can work collaboratively—across borders and disciplines—to develop a platform and comprehensive approach to reduce the time, cost and risk of developing and evaluating treatments.

We have an enormous opportunity to harness the advances that today’s science and technology offer to bring forward game-changing innovation in mental health prevention, treatment and care.

Johnson & Johnson is committed to focusing the world’s attention on this critical need, and working together with others to revolutionize the way we think about, study and approach the development of solutions so that we can change the trajectory of mental illness around the world.

Learn about career opportunities at Johnson & Johnson

Latest News

Syracuse University campus

News Roundup: TV Diversity, Syracuse Hire, and Segregated Training

Check out our news roundup of diversity and inclusion updates and insights from across the U.S.: Syracuse University Creates Athletics Diversity Position  While most colleges and universities around the county are making COVID-19-related cuts in regard to their athletic departments, Syracuse University has hired Salatha T. Willis as the associate athletic…

Cesar Conde

NBCUniversal Sets Ambitious 50% Diversity Goal for Women, People of Color

Cesar Conde, chairman at NBCUniversal News Group, announced a groundbreaking goal to have a 50% diverse workforce at NBCUniversal, according to Deadline. Conde, the first Latino in this role, outlined his plans in an internal video for employees on Wednesday. The ultimate goal is for NBCUniversal, No. 7 on DiversityInc’s 2020…

Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries

Originally published on jnj.com. Joint efforts aim to accelerate scale-up of WHO-recommended all-oral treatment regimens – a transition urgently needed to help protect the health of people with drug resistant-tuberculosis who are particularly vulnerable during COVID-19 pandemic In 2020, the initiative aims to reach at least 125,000 patients and could…

Toyota, Alabama A&M and Huntsville Hospital Collaborate to Make COVID-19 Testing Easier

Originally published on pressroom.toyota.com. $100,000 grant provides free service to the community Alabama A & M University (AAMU), Huntsville Hospital and Toyota are developing a mobile health clinic initiative to provide free COVID-19 testing to underserved communities in Madison County. Launching later this year, the mobile medical clinic program has…

Sanofi and Regeneron Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients

Originally published on sanofi.com. Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo)….

TD Bank: How a PPP Loan Saved Essential Jobs for Hundreds of Frontline Healthcare Heroes Amid COVID-19

Originally published on newscenter.td.com. Yet, “it’s not about earning a paycheck” for these medical responders A hero is defined as “a person who is admired or idealized for courage, outstanding achievements or noble qualities.” Never has that word resonated more than right now, with millions of frontline responders risking their…

Boeing Dreamlifter Transports 500,000 Protective Face Masks for Utah Students and Teachers

Originally published on boeing.mediaroom.com. Partnered with the state of Utah, Atlas Air, H.M. Cole, Cotopaxi, Flexport and UPS to deliver face masks to school districts with the greatest need Boeing [NYSE: BA] today completed its 12th COVID-19 transport mission, using a Boeing Dreamlifter to bring personal protective equipment (PPE) to the United…